Join +750K new investors every month who copy stock picks from billionaire's portfoliosSign Up Free

Tango Therapeutics Shuts Early-Stage Cancer Study Due To Liver Toxicity

Published 23/05/2024, 17:53
© Reuters.  Tango Therapeutics Shuts Early-Stage Cancer Study Due To Liver Toxicity
AZN
-
TGTX
-

Benzinga - by Vandana Singh, Benzinga Editor.

On Thursday, Tango Therapeutics Inc. (NASDAQ:TNGX) announced that it will discontinue the development of its TNG348 program.

“Patient safety is always our first priority and based on emerging data from the TNG348 dose escalation study, we have made the decision to discontinue further development of this molecule due to liver toxicity experienced by patients in the trial. While disappointing, we believe this is the right decision given the data at hand,” said Barbara Weber, President and CEO.

“We will focus resources and capital on our existing portfolio, particularly our PRMT5 program. We remain committed to and confident in our ability to deliver a comprehensive clinical update on TNG908 and TNG462 in the second half of this year.”

TNG348 was being studied in a phase 1/2 clinical trial evaluating the safety, pharmacokinetics, pharmacodynamics, and efficacy as a single agent and in combination with AstraZeneca Plc’s (NASDAQ:AZN) Lynparza (olaparib) in patients with BRCA1/2-mutant and other HRD+ (homologous recombination deficient) cancers.

Grade 3/4 liver function abnormalities were observed in patients remaining on study longer than eight weeks, leading to the decision to terminate the program.

No patient had yet received a combination of TNG348 and olaparib.

The company says the cash runway extended into 2027, and PRMT5 and CoREST clinical programs remain on track.

Earlier, Tango Therapeutics expected that its cash position of $344 million as of March 31, 2024, would provide a cash runway into late 2026.

Price Action: TNGX shares are trading 1.62% higher at $7.51 at the last check on Thursday.

Photo via Shutterstock

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Read the original article on Benzinga

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.